Breast cancer (BC) overexpressing human epidermal growth factor receptor 2 (HER2) constitute roughly 15–20 % of all cases and display a markedly aggressive phenotype, historically associated with poor outcomes (1). This evidence concerns the gene ERBB2 and breast carcinoma.